Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

C2269000

Clindamycin phosphate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Clindamycin 2-phosphate, Clindamycin 2-dihydrogen phosphate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H34ClN2O8PS
Número de CAS:
24729-96-2
Peso molecular:
504.96
Número CE:
246-433-0
Número MDL:
MFCD07793328
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329774986
NACRES:
NA.24
En este momento no podemos mostrarle ni los precios ni la disponibilidad

grado

pharmaceutical primary standard

familia API

clindamycin

fabricante / nombre comercial

EDQM

técnicas

HPLC: suitable
gas chromatography (GC): suitable

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1

Clave InChI

UFUVLHLTWXBHGZ-MWBQRTRKSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Clindamycin phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Antibacterial and antiprotozoal antibiotic of the licosamide class.
Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302,H317,H319,H362

Clasificaciones de peligro

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 4

1 of 4

Ciprofloxacin hydrochloride European Pharmacopoeia (EP) Reference Standard

C2190000

Ciprofloxacin hydrochloride

Clindamicina hydrochloride lincosamide antibiotic

Sigma-Aldrich

C5269

Clindamicina hydrochloride

Permethrin European Pharmacopoeia (EP) Reference Standard

Y0001733

Permethrin

Cefotaxime sodium salt suitable for plant cell culture, BioReagent, powder or crystals

Sigma-Aldrich

C7039

Cefotaxime sodium salt

Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Azadeh Ghaffari et al.
International wound journal, 9(2), 221-229 (2011-12-08)
Ethanol that affects hydration of skin and used in wound treatment formulations was studied here for its effect on permeation of drugs through burn eschar and to investigate the presence of a porous pathway in this barrier. In this study
Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
Michael T Jarratt et al.
Journal of drugs in dermatology : JDD, 11(3), 318-326 (2012-03-08)
Topical combination therapy containing a retinoid and an antimicrobial is an effective treatment for acne vulgaris. To evaluate the efficacy and safety of a new topical formulation containing clindamycin phosphate 1.2% and tretinoin 0.025% solubilized in an aqueous-based gel (CT
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico